文献速递外周动脉疾病

紫杉醇涂层外周动脉器械与年轻患者死亡率降低相关

Paclitaxel-Coated Peripheral Arterial Devices are Associated with Reduced Mortality in Younger Patients.
PubMed 文献 · Ann Vasc Surg · 2020-08-12

该回顾性研究纳入2011至2018年接受股腘动脉经皮介入的1170例患者,按年龄分组比较紫杉醇涂层器械与未涂层器械的长期生存。结果显示,<60岁和60-80岁患者使用紫杉醇涂层器械与4年生存率提高相关,>80岁组生存率相似,未发现紫杉醇涂层器械与死亡率增加相关。

要点

  • 在<60岁患者中,紫杉醇涂层器械组4年生存率80.7% vs 未涂层组64.4%(P=0.04)。
  • 在60-80岁患者中,紫杉醇涂层器械组4年生存率63.2% vs 未涂层组55.1%(P=0.04)。
  • 在>80岁患者中,两组4年生存率46.6% vs 32.8%(P=0.65),差异无统计学意义。

核心结论

  • 紫杉醇涂层动脉器械的使用未与死亡率增加相关,反而在年轻患者中与生存改善相关。

研究设计与样本

  • 回顾性队列研究,纳入2011至2018年接受股腘动脉经皮介入(球囊扩张、斑块旋切、支架置入或联合)的1170例连续患者。
  • 按年龄分为<60岁(n=244,20.9%)、60-80岁(n=635,54.3%)和>80岁(n=291,24.9%)三组,每组内再按是否使用紫杉醇涂层器械分组。

主要发现

  • 总体中,654例(55.9%)使用紫杉醇涂层器械,516例(44.1%)未使用;平均年龄70.4±12.6岁,男性663例(56.7%)。
  • 各年龄组紫杉醇涂层器械使用比例相似:<60岁56.2%,60-80岁57.0%,>80岁52.6%(P=0.45)。
  • <60岁患者中,紫杉醇涂层组4年生存率80.7% vs 未涂层组64.4%(P=0.04);60-80岁组63.2% vs 55.1%(P=0.04)。
  • >80岁患者中,两组4年生存率46.6% vs 32.8%(P=0.65),差异无统计学意义。

临床怎么用

  • 对于年轻(<60岁和60-80岁)股腘动脉介入患者,使用紫杉醇涂层器械可能改善远期生存,但仍需谨慎权衡,尤其在高再狭窄风险患者中。

局限性

  • 本研究为单中心回顾性设计,可能存在选择偏倚和未测量混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Paclitaxel-coated devices have been shown to decrease restenosis when used in the femoropopliteal artery. Recent reports have suggested a possible risk of increased late mortality in patients treated with paclitaxel. It has been suggested that younger patients and those with limited comorbidities may be at higher risk. Our objective was to analyze long-term mortality based on patient age comparing treatment with paclitaxel to uncoated devices. METHODS: We performed a retrospective review of 1,170 consecutive patients who underwent femoropopliteal percutaneous intervention by angioplasty, atherectomy, stent placement, or combination between 2011 and 2018. Patients were grouped by age at the time of procedure: <60 years old (n = 244, 20.9%), 60-80 years old (n = 635, 54.3%), and >80 years old (n = 291, 24.9%). Within each group, patients were further divided by use of paclitaxel. The primary outcome measure was survival assessed by Kaplan-Meier analysis. Differences between the groups were analyzed with analysis of variance. Multivariable analysis was performed using Cox proportional hazard models. RESULTS: Of the 1,170 patients who underwent femoropopliteal percutaneous intervention, 654 (55.9%) received a paclitaxel-coated device during treatment and 516 (44.1%) did not. Mean age of the overall patient cohort was 70.4 ± 12.6 years and 663 (56.7%) were male. When comparing the groups by age we found an increase in age but a decrease in the proportion of patients who smoke. The use of paclitaxel-coated devices was similar across the groups (<60 years old, 56.2%; 60-80 years old, 57.0%; >80 years old, 52.6%; P = 0.45). Demographics and comorbidities were similar between the patients treated with and without paclitaxel within each age group except more males in the <60-year-old group treated without paclitaxel and more patients with chronic limb threatening ischemia in the >80-year-old group treated with paclitaxel. In patients <60 and 60-80 years old paclitaxel use was associated with increased survival at 4 years: <60 (80.7% vs. 64.4%; P = 0.04); 60-80 (63.2% vs. 55.1%; P = 0.04). Survival was similar in the >80-year-old group (46.6% vs. 32.8%; P = 0.65). CONCLUSIONS: Our data suggest that the use of paclitaxel-coated arterial devices is not associated with increased mortality. On the contrary, our data show that younger patients treated with paclitaxel show improved survival compared with those treated without paclitaxel. Paclitaxel-coated devices may be used with continued caution especially in patients at high risk for restenosis.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Kumins NH, King AH, Ambani RN, et al. Paclitaxel-Coated Peripheral Arterial Devices are Associated with Reduced Mortality in Younger Patients. Ann Vasc Surg. 2020. PMID: 32795647. doi:10.1016/j.avsg.2020.08.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。